The US researchers at the Baylor College of Medicine, Texas Children’s Hospital have said the follow-up observations mark the ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

Think of it this way — the human body is a kingdom which is healthy, prosperous and functions peacefully. Every once in a while, invaders from the pat ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced ...

The Penn physician-researcher has received more funding to advance his 'Trojan horse' for attacking gastroesophageal cancer.

GloboCare has received a Notice of Allowance from the China National Intellectual Property Administration for its patent ...

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Some New York doctors are working on new ways to treat advanced cancers. Chimeric Antigen Receptor, or CAR, T-cell therapy treats certain blood cancers by genetically modifying a person’s T-cells to ...